TY - JOUR
T1 - LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients
AU - Akers, Stacey N.
AU - Moysich, Kirsten
AU - Zhang, Wa
AU - Collamat Lai, Golda
AU - Miller, Austin
AU - Lele, Shashikant
AU - Odunsi, Kunle
AU - Karpf, Adam R.
N1 - Funding Information:
We thank Ms. Smitha James and Ms. Petra Link for their expert technical assistance. This study was supported by the NIH grants RO1CA116674 (A.R.K.), T32CA108456 (S.N.A), and R01CA126841 (KM).
PY - 2014/2
Y1 - 2014/2
N2 - Objective We determined whether DNA methylation of repetitive elements (RE) is altered in epithelial ovarian cancer (EOC) patient tumors and white blood cells (WBC), compared to normal tissue controls. Methods Two different quantitative measures of RE methylation (LINE1 and Alu bisulfite pyrosequencing) were used in normal and tumor tissues from EOC cases and controls. Tissues analyzed included: i) EOC, ii) normal ovarian surface epithelia (OSE), iii) normal fallopian tube surface epithelia (FTE), iv) WBC from EOC patients, obtained before and after treatment, and v) WBC from demographically-matched controls. Results REs were significantly hypomethylated in EOC compared to OSE and FTE, and LINE1 and Alu methylation showed a significant direct association in these tissues. In contrast, WBC RE methylation was significantly higher in EOC cases compared to controls. RE methylation in patient-matched EOC tumors and pre-treatment WBC did not correlate. Conclusions EOC shows robust RE hypomethylation compared to normal tissues from which the disease arises. In contrast, RE are generally hypermethylated in EOC patient WBC compared to controls. EOC tumor and WBC methylation did not correlate in matched patients, suggesting that RE methylation is independently controlled in tumor and normal tissues. Despite the significant differences observed over the population, the range of RE methylation in patient and control WBC overlapped, limiting their specific utility as an EOC biomarker. However, our data demonstrate that DNA methylation is deranged in normal tissues from EOC patients, supporting further investigation of WBC DNA methylation biomarkers suitable for EOC risk assessment.
AB - Objective We determined whether DNA methylation of repetitive elements (RE) is altered in epithelial ovarian cancer (EOC) patient tumors and white blood cells (WBC), compared to normal tissue controls. Methods Two different quantitative measures of RE methylation (LINE1 and Alu bisulfite pyrosequencing) were used in normal and tumor tissues from EOC cases and controls. Tissues analyzed included: i) EOC, ii) normal ovarian surface epithelia (OSE), iii) normal fallopian tube surface epithelia (FTE), iv) WBC from EOC patients, obtained before and after treatment, and v) WBC from demographically-matched controls. Results REs were significantly hypomethylated in EOC compared to OSE and FTE, and LINE1 and Alu methylation showed a significant direct association in these tissues. In contrast, WBC RE methylation was significantly higher in EOC cases compared to controls. RE methylation in patient-matched EOC tumors and pre-treatment WBC did not correlate. Conclusions EOC shows robust RE hypomethylation compared to normal tissues from which the disease arises. In contrast, RE are generally hypermethylated in EOC patient WBC compared to controls. EOC tumor and WBC methylation did not correlate in matched patients, suggesting that RE methylation is independently controlled in tumor and normal tissues. Despite the significant differences observed over the population, the range of RE methylation in patient and control WBC overlapped, limiting their specific utility as an EOC biomarker. However, our data demonstrate that DNA methylation is deranged in normal tissues from EOC patients, supporting further investigation of WBC DNA methylation biomarkers suitable for EOC risk assessment.
KW - Alu
KW - DNA methylation
KW - Epithelial ovarian cancer
KW - LINE1
KW - Repetitive elements
UR - http://www.scopus.com/inward/record.url?scp=84894054247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894054247&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2013.12.024
DO - 10.1016/j.ygyno.2013.12.024
M3 - Article
C2 - 24374023
AN - SCOPUS:84894054247
SN - 0090-8258
VL - 132
SP - 462
EP - 467
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -